FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHA	NGES I	N BENE	FICIAL	OWNER	SHIP

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average b	urden						
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations 4(b). Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*			2. Issuer Name and Ticker or Trading Symbol Foghorn Therapeutics Inc. [FHTX]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)								
GILL SIMBA			1	1 25 10 11 1 11 1 1 1 1 1 1 1 1 1 1 1 1 1 1								V Director	r		10% Ow	ner		
	`	irst) Y SQUARE	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 07/13/2021						Officer below)	(give title		Other (s below)	pecify		
STE 700			4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Ir	6. Individual or Joint/Group Filing (Check Applicable							
(Street)	IDGE M	ÍΑ	02139				•		Ü		`	,	Line) <mark>X</mark> Form fi	led by One led by More	Repo	rting Person	
(City)	(S	tate)	(Zip)															
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3) 2. Transa Date (Month/D			Execution Date,		Code (Ir 8)			ities Acquired (A) od (D) (Instr. 3, 4		Securitie Beneficia Owned F Reported Transacti	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		Direct I Indirect E str. 4)	7. Nature of ndirect Beneficial Dwnership Instr. 4)				
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Execution Date, Gecurity or Exercise (Month/Day/Year) if any		C	Transaction Code (Instr.		of		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amoun of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Co	ode	v	(A)	(D)	Date Exercisable		Expiration Date	Title	Amount or Number of Shares					
Stock Option (right to buy)	\$9.4	07/13/2021			A		12,530		07/13/2022 ⁽	(1)	07/12/2031	Common Stock	12,530	\$0.00	12,530		D	

1. The options will vest in full on the first anniversary of the date of grant, subject to the director's continued service on our Board of Directors.

Remarks:

/s /Allan Reine, M.D., Attorney-in-Fact

07/14/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $^{^{\}star}$ If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).